Becton Dickinson And Company Stock News

AdvisorNet Financial Inc trimmed its position in Becton, Dickinson and Company (NYSE:BDX) by 94.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 165 shares of the medical instruments suppliers stock after selling 2,981 shares during the period. AdvisorNet Financial Incs []

Boenning & Scattergood Inc. grew its position in Becton, Dickinson and Company (NYSE:BDX) by 0.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,587 shares of the medical instruments suppliers stock after purchasing an additional 93 shares during []

DUBLIN--(BUSINESS WIRE)--The "Clinical Laboratory Services Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com''s offering. The global clinical laboratory services market exhibited moderate growth during 2015-2020. Looking forward, the publisher expects the market to grow at a CAGR of around 6% during 2021-2026. Companies Mentioned Abbott Laboratories Becton Dickinson Company bioMerieux SA Charles River Laborato

Businessmarketinsights Latest update on North America Drug Delivery System Market Analysis, North America Drug Delivery System market growth analysis and Projection by 2027. This report is highly predictive as it holds the overall market analysis of topmost companies into

BD's (BDX) acquisition of Venclose is expected to deliver a patient-centric approach to care.

FRANKLIN LAKES, N.J. , Dec. 6, 2021 /PRNewswire/ -- BD ( Becton, Dickinson and Company ) (NYSE: BDX), a leading global medical technology company, today announced that " embecta " [pronounced em-BECK-tah] will be the name of the independent, publicly-traded company that will hold BD''s Diabetes Care

Upcoming Ex-Dividend Dates: December 12-20, 2021

Becton Dickinson & Co. BDX, +0.90% said Monday that the spinoff of its diabetes care business will be named "embecta." The previously announced spinoff, into an independent publicly traded company, is

Oregon Public Employees Retirement Fund raised its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 1.0% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 24,353 shares of the medical instruments suppliers stock after acquiring an additional 233 shares during the []

Ellevest Inc. decreased its stake in Becton, Dickinson and Company (NYSE:BDX) by 38.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 158 shares of the medical instruments suppliers stock after selling 97 shares during the period. Ellevest Inc.s holdings in Becton, Dickinson []

CENTRAL TRUST Co lessened its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 29.2% in the third quarter, according to its most recent filing with the SEC. The firm owned 3,252 shares of the medical instruments suppliers stock after selling 1,343 shares during the quarter. CENTRAL TRUST Cos holdings in Becton, Dickinson and []

Monthly update of the Dividend Champions List. 75 companies declared higher dividends in the past month, with an average increase of 8.55% over their previous payouts.

All stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List.

BLB&B Advisors LLC grew its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 54.9% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,788 shares of the medical instruments suppliers stock after acquiring an additional 1,342 shares during the period. BLB&B Advisors LLCs holdings in []

FRANKLIN LAKES, N.J., Dec. 2, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it has acquired Venclose, Inc., a provider of solutions for the treatment of chronic venous insufficiency (CVI) a disease that